Anticancer Drugs Practice Questions

Q: Arsenic is used in the treatment of which condition?

Acute promyelocytic leukemia. **Explanation:** **Arsenic Trioxide ($As_2O_3$)** is a highly effective agent specifically used for **Acute Promyelocytic Leukemia (APL)**, which is the M3 subtype of Acute Myeloid Leukemia. **Why Option A is Correct:** APL is characterized by a specific chromosomal translocation **t(15;17)**, which creates the **PML-RARα** fusion protein. This protein blocks myeloid differentiation at the promyelocyte stage. Arsenic trioxide works by binding to the PML moiety, inducing the degradation of the fusion protein and promoting apoptosis of the leukemic cells. It is currently the standard of care for both newly diagnosed and relapsed APL, often used in combination with **All-Trans Retinoic Acid (ATRA)**. **Why Other Options are Incorrect:** * **B. Acute Lymphoblastic Leukemia (ALL):** Treated primarily with vincristine, corticosteroids, L-asparaginase, and anthracyclines. Arsenic has no established role here. * **C. Chronic Myeloid Leukemia (CML):** The mainstay of treatment is Tyrosine Kinase Inhibitors (TKIs) like **Imatinib**, which target the BCR-ABL fusion protein. * **D. Transient Myeloproliferative Disorder (TMD):** This is a self-limiting condition seen in neonates with Down Syndrome. It usually resolves spontaneously and does not require arsenic therapy. **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism:** Degradation of PML-RARα fusion protein and induction of differentiation. * **Side Effects:** The most characteristic side effect is **QT interval prolongation** (requires ECG monitoring). It can also cause **Differentiation Syndrome** (fever, dyspnea, weight gain), treated with dexamethasone. * **Historical Context:** Arsenic was historically a component of **Fowler’s solution**, used for various ailments before modern chemotherapy.

Q: Which of the following are alkylating agents?

Chlorambucil. **Explanation:** **Alkylating agents** are cell-cycle non-specific drugs that act by forming reactive carbonium ions, which create covalent bonds with DNA (primarily at the N7 position of Guanine). This leads to DNA cross-linking, strand breakage, and inhibition of replication. * **Chlorambucil (Option B):** This is a nitrogen mustard derivative and a classic example of an alkylating agent. It is primarily used in the treatment of Chronic Lymphocytic Leukemia (CLL). * **Busulfan (Option D):** While Busulfan is also an alkylating agent (an alkyl sulfonate), the question asks to identify "the" correct option among the choices provided. In many standard MCQ formats, Chlorambucil is the primary representative of the nitrogen mustard class often tested. *(Note: In a multiple-response scenario, both B and D are alkylating agents; however, Chlorambucil is the most definitive answer for nitrogen mustards).* **Why other options are incorrect:** * **Doxorubicin (Option A):** An **Antitumor Antibiotic** (Anthracycline). It works by inhibiting Topoisomerase II, intercalating between DNA base pairs, and generating free radicals. * **Vinblastine (Option C):** A **Vinca Alkaloid** (Anti-microtubule agent). It inhibits tubulin polymerization, leading to mitotic arrest in the M-phase. **High-Yield Clinical Pearls for NEET-PG:** 1. **Cyclophosphamide:** The most widely used alkylating agent; causes **hemorrhagic cystitis** (prevented by **MESNA** and hydration). 2. **Busulfan:** Specifically associated with **pulmonary fibrosis** ("Busulfan lung") and skin hyperpigmentation. 3. **Nitrosoureas (Lomustine, Carmustine):** Alkylating agents with high lipid solubility, making them the drugs of choice for **brain tumors**. 4. **Dacarbazine:** An alkylating agent used in the ABVD regimen for Hodgkin’s Lymphoma.

Q: Aromatase inhibitors are used in the treatment of which of the following cancers?

Breast cancer. **Explanation:** **Aromatase inhibitors (AIs)**, such as Letrozole, Anastrozole, and Exemestane, are the treatment of choice for hormone receptor-positive (ER/PR+) **breast cancer** in postmenopausal women. The underlying medical concept involves the synthesis of estrogen. In postmenopausal women, the ovaries stop producing estrogen; instead, the enzyme **aromatase** converts adrenal androgens (androstenedione and testosterone) into estrogens (estrone and estradiol) in peripheral tissues like fat and muscle. Since many breast tumors are estrogen-dependent, inhibiting this enzyme deprives the tumor cells of the growth signals they need, leading to tumor regression. **Analysis of Incorrect Options:** * **A. Lung Cancer:** Primarily treated with surgery, radiotherapy, and chemotherapy (e.g., Cisplatin) or targeted therapies (e.g., EGFR inhibitors like Erlotinib), but not hormonal manipulation via aromatase. * **C. Liver Cancer (HCC):** Management involves surgical resection, kinase inhibitors (e.g., Sorafenib), or transplant; it is not driven by estrogen pathways. * **D. Colon Cancer:** Standard treatment involves the FOLFOX regimen (5-Fluorouracil, Leucovorin, Oxaliplatin). It does not respond to aromatase inhibition. **High-Yield Clinical Pearls for NEET-PG:** * **Drug of Choice:** AIs are preferred over Tamoxifen in **postmenopausal** women because they are more effective and lack the risk of endometrial cancer. * **Tamoxifen vs. AIs:** Tamoxifen is a SERM used in **premenopausal** women. AIs are ineffective in premenopausal women because they cannot overcome the high estrogen production from functional ovaries. * **Side Effects:** The most characteristic side effect of AIs is **osteoporosis** and increased risk of fractures (due to total estrogen deprivation), whereas Tamoxifen increases the risk of **thromboembolism** and **endometrial carcinoma**.

Q: Which of the following anticancer agents has specific activity in a subset of female breast cancers?

Trastuzumab. **Explanation:** **Trastuzumab** is the correct answer because it is a recombinant DNA-derived humanized monoclonal antibody specifically designed to target the **HER2/neu (ErbB2) receptor**. This receptor is overexpressed in approximately 15–25% of female breast cancers. Trastuzumab inhibits the proliferation of tumor cells that overexpress HER2, making its activity specific to this molecular subset. **Analysis of Incorrect Options:** * **Anastrozole:** While used in breast cancer, it is a non-steroidal **Aromatase Inhibitor**. It works by blocking the peripheral conversion of androgens to estrogens. It is used in postmenopausal women with estrogen receptor-positive (ER+) cancer, but it is not considered "subset-specific" in the same targeted molecular context as Trastuzumab. * **Doxorubicin:** An anthracycline antibiotic that acts via DNA intercalation and inhibition of Topoisomerase II. It is a **broad-spectrum** cytotoxic agent used in many cancers (including breast cancer) regardless of specific receptor subsets. * **Fluoxymesterone:** An oral androgen occasionally used as palliative therapy in breast cancer, but it lacks the targeted specificity for a modern molecular subset. **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism of Trastuzumab:** Binds to the extracellular domain of HER2; induces cell cycle arrest and antibody-dependent cellular cytotoxicity (ADCC). * **Key Side Effect:** **Cardiotoxicity** (manifests as a decrease in LVEF/congestive heart failure). Unlike Doxorubicin, Trastuzumab-induced cardiotoxicity is usually **reversible** and not dose-dependent. * **Monitoring:** Baseline and periodic Echocardiography/MUGA scans are mandatory. * **Combination Warning:** Never combine Trastuzumab with Anthracyclines (like Doxorubicin) due to synergistic cardiotoxicity.

Q: All of the following anticancer drugs act on the G2 phase except?

Paclitaxel. **Explanation:** The cell cycle consists of specific phases (G1, S, G2, M), and many anticancer drugs are **cell-cycle specific**. To answer this question, one must distinguish between drugs acting on the **G2 phase** (pre-mitotic interval) and the **M phase** (mitosis). **1. Why Paclitaxel is the correct answer:** **Paclitaxel** (a Taxane) acts specifically on the **M phase**. Its mechanism involves stabilizing microtubules and inhibiting their depolymerization. This prevents the formation of the mitotic spindle, leading to mitotic arrest. Since it acts on the M phase and not the G2 phase, it is the "except" in this list. **2. Analysis of incorrect options (Drugs acting on G2):** * **Bleomycin:** This is a classic G2-specific drug. It causes DNA fragmentation by generating free radicals, arresting cells in the **G2 phase**. * **Etoposide:** A Topoisomerase II inhibitor. While it has some activity in the S phase, its primary lethal effect occurs in the **late S and G2 phases**. * **Irinotecan:** A Topoisomerase I inhibitor. These drugs typically cause arrest in the **S and G2 phases** by preventing the religation of DNA strands. **High-Yield Clinical Pearls for NEET-PG:** * **M-Phase Specific:** Vinca alkaloids (Vincristine/Vinblastine) and Taxanes (Paclitaxel/Docetaxel). * **S-Phase Specific:** Antimetabolites (Methotrexate, 5-FU, Cytarabine). * **G2-Phase Specific:** Bleomycin and Etoposide. * **Cell-Cycle Non-Specific (CCNS):** Alkylating agents (Cyclophosphamide) and Platinum compounds (Cisplatin). * **Side Effect Tip:** Bleomycin is notorious for **Pulmonary Fibrosis**, while Paclitaxel is known for **Peripheral Neuropathy** and hypersensitivity reactions.

Q: All of the following statements about vincristine are true EXCEPT?

It is a drug of choice for solid tumors. **Explanation:** **1. Why Option D is the Correct Answer (The "Except" statement):** Vincristine is primarily used in the treatment of **hematological malignancies** (e.g., Acute Lymphoblastic Leukemia, Hodgkin’s and Non-Hodgkin’s Lymphoma) and specific pediatric tumors (e.g., Wilms' tumor). While it is part of combination regimens for some solid tumors, it is **not** considered a general "drug of choice" for the broad category of adult solid tumors (like breast, lung, or colon cancer), where drugs like taxanes, platinum compounds, or 5-FU are preferred. **2. Analysis of Other Options:** * **Option A (Inhibits Mitosis):** Vincristine is a **Vinca alkaloid** that binds to tubulin and prevents its polymerization into microtubules. This causes **mitotic arrest in the M-phase**, specifically preventing the formation of the mitotic spindle. * **Option B (Peripheral Neuropathy):** This is the **dose-limiting toxicity** of vincristine. It interferes with axonal microtubule transport, leading to symmetrical sensory-motor neuropathy, paresthesia, and loss of deep tendon reflexes. * **Option C (Does not suppress bone marrow):** Vincristine is unique among traditional cytotoxic drugs because it is **bone marrow sparing**. This makes it an ideal component for combination chemotherapy (e.g., the MOPP or CHOP regimens) as it does not add to the myelosuppression caused by other agents. **NEET-PG High-Yield Pearls:** * **Vincristine vs. Vinblastine:** Remember the mnemonic: **"B"** for Vin**b**lastine = **B**one marrow suppression; **"C"** for Vin**c**ristine = **C**onstipation (autonomic neuropathy) and **C**entral/Peripheral nerve damage. * **Fatal Route:** Vincristine is for **Intravenous (IV) use only**. Intrathecal administration is fatal due to progressive neurotoxicity. * **SIADH:** Vincristine is a well-known cause of the Syndrome of Inappropriate Antidiuretic Hormone secretion.

Q: What is the drug of choice for the T790M mutation of EGFR in Non-Small Cell Lung Cancer?

Osimertinib. **Explanation:** **Osimertinib** is the correct answer because it is a **third-generation irreversible EGFR Tyrosine Kinase Inhibitor (TKI)** specifically designed to target the **T790M resistance mutation**. In Non-Small Cell Lung Cancer (NSCLC), patients treated with first-generation TKIs (like Gefitinib or Erlotinib) often develop resistance via the T790M mutation, which increases the ATP affinity of the EGFR kinase domain. Osimertinib selectively inhibits both sensitizing mutations and the T790M resistance mutation while sparing wild-type EGFR, reducing skin and GI toxicity. **Analysis of Incorrect Options:** * **Lapatinib:** A dual TKI targeting both **EGFR (ErbB1) and HER2 (ErbB2)**. It is primarily used in HER2-positive breast cancer, not for T790M-mutated lung cancer. * **Crizotinib:** An inhibitor of **ALK (Anaplastic Lymphoma Kinase)**, ROS1, and MET. It is the drug of choice for ALK-positive NSCLC, but ineffective against EGFR mutations. * **Alemtuzumab:** A monoclonal antibody against **CD52**, used in Chronic Lymphocytic Leukemia (CLL) and Multiple Sclerosis, with no role in EGFR-mutated lung cancer. **High-Yield Clinical Pearls for NEET-PG:** * **Generations of EGFR TKIs:** * 1st Gen (Reversible): Gefitinib, Erlotinib. * 2nd Gen (Irreversible): Afatinib, Dacomitinib. * 3rd Gen (T790M specific): **Osimertinib**. * **Adverse Effect:** While Osimertinib has fewer skin rashes than 1st gen drugs, it can cause **QT interval prolongation** and cardiomyopathy. * **Blood-Brain Barrier:** Osimertinib has excellent CNS penetration, making it preferred for patients with brain metastases.

Q: Arsenic compounds are used for the treatment of which of the following cancers?

Acute Promyelocytic Leukemia (APML). **Explanation:** **Arsenic Trioxide ($As_2O_3$)** is a highly effective treatment for **Acute Promyelocytic Leukemia (APML)**, specifically for patients who are refractory to or have relapsed after treatment with All-Trans Retinoic Acid (ATRA). **Why the correct answer is right:** APML (FAB M3 subtype) is characterized by the $t(15;17)$ translocation, which creates the **PML-RARα fusion protein**. This protein arrests myeloid differentiation at the promyelocyte stage. Arsenic Trioxide works through a dual mechanism: 1. **Degradation of the PML-RARα protein:** It binds directly to the PML moiety, inducing its degradation and allowing the cells to differentiate. 2. **Induction of Apoptosis:** It triggers the mitochondrial pathway of programmed cell death in leukemic cells. **Why incorrect options are wrong:** * **CLL (B):** Primarily treated with BTK inhibitors (Ibrutinib), BCL-2 inhibitors (Venetoclax), or anti-CD20 monoclonal antibodies (Rituximab). * **ALL (C):** Managed with a combination of Vincristine, L-Asparaginase, Corticosteroids, and Anthracyclines. * **CML (D):** The mainstay of treatment is Tyrosine Kinase Inhibitors (TKIs) like **Imatinib**, which target the BCR-ABL fusion protein. **High-Yield Clinical Pearls for NEET-PG:** * **Side Effects:** The most critical side effect of Arsenic Trioxide is **QT interval prolongation**, which can lead to Torsades de Pointes. Regular ECG monitoring is mandatory. * **Differentiation Syndrome:** Similar to ATRA, Arsenic can cause "Differentiation Syndrome" (fever, dyspnea, weight gain, pulmonary infiltrates), treated with high-dose **Dexamethasone**. * **Historical Context:** Arsenic was historically used as "Fowler’s Solution," but its modern use is strictly limited to APML.

Q: Which chemotherapeutic agent is used in brain tumors?

Nitrosoureas. **Explanation:** The primary challenge in treating brain tumors is the **Blood-Brain Barrier (BBB)**, a highly selective semipermeable border that prevents most hydrophilic and large-molecular-weight drugs from entering the central nervous system (CNS). **Why Nitrosoureas are correct:** Nitrosoureas (such as **Lomustine (CCNU), Carmustine (BCNU), and Semustine**) are the drugs of choice for primary brain tumors (e.g., Glioblastoma Multiforme). Their efficacy stems from their **high lipid solubility** and non-ionized state, which allows them to readily cross the BBB. They act by alkylating DNA and inhibiting DNA repair enzymes. **Analysis of Incorrect Options:** * **Cisplatin:** While it is a potent platinum-based alkylating agent used for various solid tumors (lung, ovary, bladder), it has **poor CNS penetration** and is not a primary choice for brain tumors. * **Bleomycin:** This is a glycopeptide antibiotic that causes DNA strand scission. It is a large, polar molecule with **negligible BBB penetration**. Its major dose-limiting toxicity is pulmonary fibrosis. * **Vincristine:** A Vinca alkaloid that inhibits microtubule polymerization. It has **very poor CNS entry** and is primarily used in leukemias and lymphomas. Interestingly, it is notorious for causing peripheral neuropathy but lacks central neurotoxicity because it cannot cross the BBB. **High-Yield Clinical Pearls for NEET-PG:** * **Temozolomide:** An oral alkylating agent that also crosses the BBB; it is currently the first-line standard of care for Glioblastoma. * **Carmustine Wafers (Gliadel):** These are biodegradable polymers implanted directly into the tumor cavity after surgical resection to bypass the BBB. * **Procarbazine:** Another lipid-soluble drug used in the PCV regimen (Procarbazine, CCNU, Vincristine) for brain tumors.

Question 1

Arsenic is used in the treatment of which condition?

Accepted Answer

Acute promyelocytic leukemia

Answer

Acute lymphoblastic leukemia

Answer

Chronic myeloid leukemia

Answer

Transient myeloproliferative disorder

Question 2

Which of the following are alkylating agents?

Accepted Answer

Chlorambucil

Answer

Doxorubicin

Answer

Vinblastine

Answer

Busulfan

Question 3

Aromatase inhibitors are used in the treatment of which of the following cancers?

Accepted Answer

Breast cancer

Answer

Lung cancer

Answer

Liver cancer

Answer

Colon cancer

Question 4

A 23-year-old female presented with palpable lumps in the axilla and supra-clavicular region. Following investigations including X-ray, USG-guided biopsy, and HPE, a diagnosis was made. Flow cytometry revealed CD15 and CD30 positivity. She was started on chemotherapy. Later, the patient developed fatigue, dyspnea, and orthopnea, with ECG showing left ventricular hypertrophy. Which of the following chemotherapeutic agents is most likely responsible for these manifestations?

Accepted Answer

Bleomycin

Answer

Daunorubicin

Answer

Capecitabine

Answer

Cyclophosphamide

Question 5

Which of the following anticancer agents has specific activity in a subset of female breast cancers?

Accepted Answer

Trastuzumab

Answer

Anastrozole

Answer

Doxorubicin

Answer

Fluoxymesterone

Question 6

All of the following anticancer drugs act on the G2 phase except?

Accepted Answer

Paclitaxel

Answer

Etoposide

Answer

Irinotecan

Answer

Bleomycin

Question 7

All of the following statements about vincristine are true EXCEPT?

Accepted Answer

It is a drug of choice for solid tumors

Answer

It acts by inhibiting mitosis

Answer

Its prominent adverse effect is peripheral neuropathy

Answer

It does not suppress bone marrow

Question 8

What is the drug of choice for the T790M mutation of EGFR in Non-Small Cell Lung Cancer?

Accepted Answer

Osimertinib

Answer

Lapatinib

Answer

Crizotinib

Answer

Alemtuzumab

Question 9

Arsenic compounds are used for the treatment of which of the following cancers?

Accepted Answer

Acute Promyelocytic Leukemia (APML)

Answer

Chronic Lymphocytic Leukemia (CLL)

Answer

Acute Lymphoblastic Leukemia (ALL)

Answer

Chronic Myeloid Leukemia (CML)

Question 10

Which chemotherapeutic agent is used in brain tumors?

Accepted Answer

Nitrosoureas

Answer

Cisplatin

Answer

Bleomycin

Answer

Vincristine

Anticancer Drugs — MCQs

Anticancer Drugs — MCQs

On this page

Practice by Chapter

Want unlimited practice?